|
Mar 21
|
Medicare Will Cover Weight-Loss Drugs — For Some. Here's What It Means For Novo, Lilly.
|
|
Feb 15
|
Ozempic, Mounjaro and hundreds of other drugs become even more expensive in 2024
|
|
Feb 15
|
What's Gaining Popularity Among US Teens Battling Obesity? Novo Nordisk's Weight Loss Drug Wegovy
|
|
Feb 14
|
UPDATE 1-Britain sees launch of Lilly's weight-loss drug Mounjaro
|
|
Feb 14
|
Britain sees launch of Lilly's weight-loss drug Mounjaro
|
|
Feb 14
|
1 Potential Catalyst That Could Light a Fire Under Novo Nordisk's Stock This Year
|
|
Feb 14
|
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
|
|
Feb 14
|
Amgen Takes Aim at Novo Nordisk and Eli Lilly, but Is the Stock a Buy?
|
|
Feb 13
|
Move Aside, Eli Lilly and Novo Nordisk. Wall Street Thinks This Stock Will Be a Bigger Winner Over the Next 12 Months.
|
|
Feb 12
|
Why Novo Nordisk (NVO) is a Top Stock for the Long-Term
|
|
Feb 12
|
Novo Nordisk's Magic Run Continues Even With Increasing Competition
|
|
Feb 12
|
Beat the Market Like Zacks: Costco, GigaCloud, Novo Nordisk in Focus
|
|
Feb 12
|
Wall Street's Next Stock-Split Stocks Are Liable to Be Familiar Names
|
|
Feb 12
|
Could Eli Lilly's Zepbound Become the World's Best-Selling Drug?
|
|
Feb 12
|
Novo Nordisk's controlling shareholder plans to invest about $35 billion by 2030
|
|
Feb 12
|
UPDATE 2-Novo Nordisk's controlling shareholder plans to invest about $35 bln by 2030
|
|
Feb 11
|
Abbott Laboratories Is the Latest Company to Get Involved in the Weight Loss Market. Here's How.
|
|
Feb 11
|
Novo Nordisk Is Scaling a Barrier to Growth. Should You Buy Its Stock Now?
|
|
Feb 11
|
Don't Worry About Novo Nordisk's Premium Stock Price. It's Still a Buy.
|
|
Feb 10
|
CVS chief medical officer: 'We are not looking to build the entire healthcare delivery ecosystem'
|